Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing effective, safe, and accessible cell therapies for patients suffering from devastating autoimmune diseases and cancers. The company's mission centers on harnessing the power of natural killer (NK) cells to create innovative treatments. Headquartered in San Diego, California, Artiva was founded in 2019.

Artiva specializes in the development of off-the-shelf, allogeneic NK cell therapies. Its lead product candidate, AlloNK (also referred to as AB-101), is a non-genetically modified, cryopreserved NK cell therapy designed to enhance the activity of monoclonal antibodies. AlloNK is currently undergoing clinical evaluation in combination with B-cell targeted monoclonal antibodies for various autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, Sjögren's disease, and lupus nephritis, as well as for certain cancers like B-cell non-Hodgkin lymphoma. The company's pipeline also includes chimeric antigen receptor (CAR)-NK candidates such as AB-201, targeting HER2 for solid tumors, and AB-205, targeting CD5 for hematological malignancies.

Artiva Biotherapeutics became a publicly traded company on July 19, 2024, listing on the NASDAQ Global Market under the ticker symbol ARTV. The company is prioritizing refractory rheumatoid arthritis (RA) as the lead indication for AlloNK, which received FDA Fast Track Designation for this condition in combination with rituximab in October 2025. Artiva anticipates releasing initial clinical response data for AlloNK in refractory RA in the first half of 2026 and plans to engage with the FDA regarding the design of a potential pivotal trial. Recent leadership appointments include Subhashis Banerjee as Chief Medical Officer in April 2025 and Thad Huston as Chief Financial Officer in February 2026. As of the end of 2025, Artiva reported $108 million in cash, cash equivalents, and investments, providing operational runway into the second quarter of 2027.